• 2010

Company Description

RepliCel Life Sciences engages in developing hair follicle cell replication technology for patients suffering from androgenetic alopecia.

RepliCel’s current research activity is focused on the company’s core understanding of the unique biological function of hair follicle cells. Two distinct autologous cell therapies are currently in development. The first is a cellular treatment for androgenetic alopecia (pattern baldness) named RepliCel Hair-01 (RCH-01). The second is a cell therapy for the treatment of chronic tendon injuries named RepliCel Tendon-01 (RCT-01).